Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Analysts

Cara Therapeutics, Inc. (NASDAQ:CARA) has been assigned a consensus recommendation of “Hold” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $27.84.

Separately, StockNews.com began coverage on shares of Cara Therapeutics in a research report on Wednesday, January 8th. They issued a “sell” rating on the stock.

Cara Therapeutics Stock Up 5.9 %

Shares of CARA stock opened at $5.06 on Friday. The business’s fifty day moving average is $4.21 and its 200 day moving average is $3.92. The stock has a market cap of $23.12 million, a price-to-earnings ratio of -0.24 and a beta of 0.51. Cara Therapeutics has a twelve month low of $2.71 and a twelve month high of $13.80.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CARA. Disciplined Growth Investors Inc. MN increased its holdings in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 120,660 shares in the last quarter. FMR LLC grew its position in Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Cara Therapeutics during the 3rd quarter valued at about $29,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.